Results 21 to 30 of about 4,128,106 (288)

Antiparasitic Drugs in the United States—Two Roads to High Prices

Frontiers in Sociology, 2020
High prescription drug prices contribute significantly to healthcare spending in the United States and compromise patients' access to quality medical care.
Arman A. Shahriar, Jonathan D. Alpern, Jonathan D. Alpern   +2 more
doaj   +1 more source

Decision-making on listing new medicines for public funding in New Zealand: the case of 'new' type 2 diabetes medications [PDF]

Journal of Primary Health Care, 2022
IntroductionNew medicines for the management of type 2 diabetes became available internationally in 2005, yet only in 2018 did the first of these become available in New Zealand.
Caroline Stretton, Charon Lessing, Farzana Sarkisova   +2 more
doaj  

Direct healthcare costs and their relationships with age at start of drug use and current pattern of use: a cross-sectional study

São Paulo Medical Journal, 2021
BACKGROUND: It is well known that early start of drug use can lead users to psychosocial problems in adulthood, but its relationship with users’ direct healthcare costs has not been well established OBJECTIVES: To estimate the direct healthcare costs ...
Paula Becker, Denise Razzouk
doaj   +1 more source

Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales

Orphanet Journal of Rare Diseases, 2023
Background The Orphan Regulation ((EC) No 141/2000) has successfully redirected private and public investment towards previously neglected areas through incentives, regulatory obligations and rewards.
Yankier Pijeira Perez, Eifiona Wood, Dyfrig A Hughes   +2 more
doaj   +1 more source

Corifollitropin alfa versus daily recombinant FSH for ovarian stimulation in women of advanced maternal age: a cost-minimization analysis in an out-of-pocket setting

Frontiers in Reproductive Health
BackgroundIn many countries, Assisted Reproductive Technology (ART) remains funded predominantly out-of-pocket, with no private insurance reimbursement and only limited public provision.
G. N. Cecchino, B. R. Carvalho, B. R. Carvalho, Y. Ramires, R. L. P. Bueno, R. L. P. Bueno, L. A. Lucio, V. P. Santana   +7 more
doaj   +1 more source

Out-of-pocket expenditure for administration of benzathine penicillin G injections for secondary prophylaxis in patients with rheumatic heart disease: A registry-based data from a tertiary care center in Northern India

Indian Heart Journal, 2021
Background: Costs can be a major barrier to medication adherence in low and middle-income countries and are an important target for policy-level interventions.
Balaji Arvind, Anita Saxena, Dhruv S. Kazi, Ann F. Bolger   +3 more
doaj   +1 more source

New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Current Oncology
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation.
David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist   +14 more
doaj   +1 more source

Consórcio de medicamentos no Paraná: análise de cobertura e custos A drug consortium in Paraná: analysis of coverage and costs

Revista de Administração Pública, 2007
A redução de custos na compra de medicamentos é preocupação constante dos administradores públicos. Este artigo analisa a cobertura e custos do Consórcio Paraná Saúde (CPS), constituído para aquisição de medicamentos para prefeituras do Paraná.
Alide Marina Biehl Ferraes, Luiz Cordoni Junior   +1 more
doaj   +1 more source

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk, Sebastian Michaelis, Michaela Döring, Thomas Eichholz, Ursula Holzer, Martin Ebinger, Tim Flaadt, Rupert Handgretinger, Peter Lang, Jan Frederic Weller, Markus Mezger   +10 more
wiley   +1 more source

The processes of reform in Victoria’s alcohol and other drug sector, 2011-2014 [PDF]

, 2014
This paper explores issues and concerns related to the 2014 alcohol and other drug sector recommissioning process in Victoria. Overview In mid-2014, the Victorian Alcohol and Drug Association approached the Drug Policy Modelling Program, at the ...
Drug Policy Modelling Program
core